Company news
Pluri Inc. (NASDAQ:PLUR) news
Pluri Inc. news releases on 6ix. Latest, Aug 27, 2026: Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement…
Press releases & updates
Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor
August 27, 2026
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
August 17, 2026
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
July 28, 2026
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
July 14, 2026
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
June 2, 2026
Plurilock Announces Payment of Debenture Interest
March 31, 2026
Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
March 26, 2026
Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
February 18, 2026
Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
January 22, 2026
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
December 22, 2025
Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
December 9, 2025
Pluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the Year
November 13, 2025
Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare
November 11, 2025
Leading Global Players Back and Fund Pluri’s Cell-Based Food and Agriculture Collaborations
November 10, 2025
Plurilock Announces Insider Share Purchases
October 27, 2025
Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico
October 8, 2025
Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion
May 15, 2025
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
April 28, 2025
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
April 10, 2025
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness
March 5, 2025
Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million
February 3, 2025
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
January 22, 2025
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority
October 27, 2024
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
July 17, 2024
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply
July 7, 2024
Pluri Inc. Announces 1-for-8 Reverse Share Split
March 26, 2024
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
March 13, 2024
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
March 5, 2024
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
January 22, 2024
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
January 7, 2024
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
July 12, 2023
Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products
April 26, 2023
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
July 24, 2022
Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
February 23, 2022
Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
November 14, 2021
Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors
July 18, 2021
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
February 1, 2021
Pluristem Announces Uplisting to the Nasdaq Global Market®
January 26, 2021
Pluristem Announces Appointments of Two Directors to Board
January 5, 2021
Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
December 8, 2020
Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study
October 12, 2020
Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial
August 26, 2020
Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study
August 18, 2020
Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
June 10, 2020
Pluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 Million
May 4, 2020
Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure
April 6, 2020
Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock
April 2, 2019